Calithera Biosciences, Inc.(CALA): For the most recent quarter end, Calithera Biosciences, Inc. reported Annual Earnings of $-0.44. Based on the filings, last years Annual Earnings was, $-1.81. For the most recent quarter end, CALA reported a surprise Earnings per Share of 6.38% . The consensus estimate for current quarter is $-0.48 and for the current fiscal year, the estimate is $-1.98. For the Next fiscal year, the estimate is $-1.63 based on the consensus.
Calithera Biosciences, Inc. has received $-0.48 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.5 while the top line estimate is $-0.46 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -9.09%. Calithera Biosciences, Inc. reported better than expected with a surprise EPS of 6.38% or $0.03 during its most recent quarterly earnings. The Actual EPS was $-0.44 compared to the Estimated EPS of $-0.47.
Company has reported several Insider transactions to the SEC, on Nov 18, 2015, Curtis Hecht (VP, BUS. & CORP. DEVELOPMENT) sold 970 shares at 6.58 per share price.
Calithera Biosciences, Inc. (NASDAQ:CALA) witnessed a decline in the market cap on Wednesday as its shares dropped 2.22% or 0.2 points. After the session commenced at $8.95, the stock reached the higher end at $8.95 while it hit a low of $8.305. With the volume soaring to 677,521 shares, the last trade was called at $8.8. The company has a 52-week high of $9.8. The company has a market cap of $204 million and there are 23,222,272 shares in outstanding. The 52-week low of the share price is $2.2.
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Companys lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.